Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Frequently asked questions
What sector does SILENCE THERAP. SP.ADR/1 (XRP2) operate in?
SILENCE THERAP. SP.ADR/1 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is SILENCE THERAP. SP.ADR/1 (XRP2) current stock price?
As of the latest data, SILENCE THERAP. SP.ADR/1 stock price is €17.50, with a previous close of €17.10. SILENCE THERAP. SP.ADR/1 gained €0.40 in the last trading session, representing a 2.34% increase.
What is SILENCE THERAP. SP.ADR/1 (XRP2) current market capitalization?
SILENCE THERAP. SP.ADR/1 market cap is approximately 1.09 billion.
What is SILENCE THERAP. SP.ADR/1 (XRP2) Earnings Per Share (EPS)?
The trailing EPS is -€1.12.
Does SILENCE THERAP. SP.ADR/1 (XRP2) pay dividends?
No. SILENCE THERAP. SP.ADR/1 does not pay a dividend.
When is SILENCE THERAP. SP.ADR/1 (XRP2) next earnings report?
SILENCE THERAP. SP.ADR/1 is expected to release its next earnings report on September 30, 2026.
What is SILENCE THERAP. SP.ADR/1 (XRP2) beta (volatility) score?
SILENCE THERAP. SP.ADR/1 has a beta of 1.444, suggesting it is more volatile than the market.
